Eph-Ephrin Tetramerization Inhibitors Target Bidirectional Signaling to Combat Pain and Addiction

Eight-hydroxyquinoline small molecules disrupt tetramer-driven EphB1–EphrinB2 and EphB2–EphrinB2 interactions, reducing bidirectional EphB forward and EphrinB reverse signaling.

• Why it matters: Eph/Ephrin pathways are implicated in chronic pain and fibrosis, but there is a need for small-molecule tools that specifically interfere with tetramer-dependent bidirectional signaling.
• What they did: The study screened small molecules for disrupted EphB–EphrinB receptor-ligand binding and identified orally available 8-hydroxyquinoline compounds with preferential activity against tetramer-driven interactions.
• The result: The compounds reduce EphB forward signaling and EphrinB reverse signaling and blunt inflammatory pain and opioid withdrawal, consistent with targeting the high-affinity circular tetramer structure.

AI summary of the abstract · may contain errors · not medical advice · read the paper.